Liposomal Nasal Spray versus Guideline-Recommended Steroid Nasal Spray in Patients with Chronic Rhinosinusitis: A Comparison of Tolerability and Quality of Life

Table 6

SNOT-20 subscales:primary nasal symptoms, secondary rhinogenic symptoms, and general quality of life.

	V1	V2	V3	V4	V5	Improvement; V1–V5
Liposomal nasal spray
Primary nasal symptoms
MV	40.24	31.02	28.57	26.20	24.90	15.34
SD	14.976	13.204	17.531	18.295	18.042	−3.066
Secondary rhinogenic symptoms
MV	32.52	20.68	21.97	19.52	18.44	14.08
SD	17.220	15.811	14.528	14.337	14.563	2.657
General quality of life
MV	29.22	21.42	18.39	16.78	15.70	13.52
SD	16.726	17.451	16.341	16.217	15.634	1.092
Beclomethasone
Primary nasal symptoms
MV	45.00	33.33	31.33	28.33	28.50	16.5
SD	3.012	3.441	4.231	4.100	3.601	−0.589
Secondary rhinogenic symptoms
MV	35.00	28.89	27.64	25.14	24.86	10.14
SD	19.009	17.629	20.489	20.990	21.714	−2.731
General quality of life
MV	40.10	29.18	26.57	25.51	25.99	14.11
SD	24.255	21.496	22.267	25.662	25.806	−1.551